|
|||
|
DRUGS & SUPPLEMENTS
|
Dermazole
How is the drug helping you? |
Dermazole uses
- Indications and usage
- Dosage and administration
- Dosage forms and strengths
- Contraindications
- Warnings and precautions
- Adverse reactions
- Drug interactions
- Use in specific populations
- Description
- Clinical pharmacology
- Nonclinical toxicology
- Clinical studies
- How supplied/ storage and handling
- Patient counseling information
- Instructions for use
1 INDICATIONS AND USAGE
Dermazole (econazole nitrate) topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.
Dermazole is an azole antifungal indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. (1)
2 DOSAGE AND ADMINISTRATION
Dermazole topical foam, 1% is for topical use only. Dermazole topical foam, 1% is not for oral, ophthalmic, or intravaginal use.
Dermazole topical foam, 1% should be applied to cover affected areas once daily for 4 weeks.
- For topical use only; not for oral, ophthalmic, or intravaginal use. (2)
- Apply once daily for 4 weeks. (2)
3 DOSAGE FORMS AND STRENGTHS
Foam, 1%. Each gram of Dermazole topical foam, 1%, contains 10 mg of Dermazole in a white to off-white foam.
Foam, 1%. (3)
4 CONTRAINDICATIONS
None.
None. (4)
5 WARNINGS AND PRECAUTIONS
Contents are flammable. Instruct the patient to avoid heat, flame, and/or smoking during and immediately following application.
5.1 Flammability
Dermazole topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty. Do not store in direct sunlight.
6 ADVERSE REACTIONS
During clinical trials with Dermazole topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Dermazole and vehicle arms.
To report SUSPECTED ADVERSE REACTIONS, contact Exeltis USA Dermatology, LLC. at 1-877-324-9349 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two double-blind, vehicle-controlled clinical trials, 495 subjects were exposed to Dermazole topical foam or vehicle (246 subjects were exposed to Dermazole topical foam, 1% and 249 were exposed to vehicle). Subjects with interdigital tinea pedis applied foam or vehicle once daily for approximately 28 days. During clinical trials with Dermazole topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Dermazole and vehicle arms.
7 DRUG INTERACTIONS
7.1 Warfarin
Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect. Most cases reported product application with use under occlusion, genital application, or application to a large body surface area which may increase the systemic absorption of Dermazole. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category C
There are no adequate and well-controlled trials with Dermazole topical foam in pregnant women. Dermazole topical foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Dermazole has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment I oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.
8.3 Nursing Mothers
It is not known whether Dermazole is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Dermazole is administered to a nursing woman. Following oral administration of Dermazole to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups.
8.4 Pediatric Use
Of the 173 subjects treated with Dermazole topical foam, 1% in the clinical trials, 2 subjects were 12-17 years old. In a pediatric maximal use trial, Dermazole topical foam, 1% was applied once daily to eighteen subjects aged 12 to 17 years with interdigital tinea pedis for 28 days [see Clinical Pharmacology ]. The safety findings for subjects 12 to 17 years were similar to those in adult population.
8.5 Geriatric Use
Of the 173 subjects treated with Dermazole topical foam, 1% in the adult clinical trials, 6 subjects were 65 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.
11 DESCRIPTION
Dermazole (econazole nitrate) topical foam, 1% contains the azole antifungal agent, Dermazole in an oil-in-water emulsion base consisting of the following inactive ingredients: dimethicone, glycerin, polysorbate 20, povidone, propylene glycol, stearic acid, trolamine, purified water and butane as a propellant. Each gram of Dermazole topical foam, 1% contains 10 mg of Dermazole, USP, in a white to off-white foam. Dermazole topical foam, 1% is alcohol (ethanol)-free and for topical use only.
Chemically, Dermazole is 1-[2-{(4-chloro-phenyl)methoxy}-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole mononitrate. Dermazole has the molecular formula C18H15Cl3N2O.HNO3 and a molecular weight of 444.70. Its molecular structure is as follows:
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Dermazole topical foam is an azole antifungal [see Clinical Pharmacology ] .
12.2 Pharmacodynamics
The pharmacodynamics of Dermazole topical foam, 1% have not been established.
12.3 Pharmacokinetics
The systemic absorption of Dermazole topical foam, 1% following topical application was studied in one clinical trial in adults and one clinical study in pediatric subjects.
In the adult trial, 19 subjects with tinea pedis applied Dermazole topical foam, 1% once daily for 29 days. Subjects applied a mean daily amount of 2.4 g of Dermazole topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 29 at pre-dose and 1, 2, 4, 6, 8, and 12 hours after application. Results (mean ± SD) showed the time to reach peak plasma concentrations (Tmax) was 6.8 ± 5.1 h with maximum concentration (Cmax) of 417 ± 218 pg/ml. The area under the concentration time curve for the first 12 hours post application on Day 29 (AUC(0-12)) was 3440 ± 1920 pg-h/ml.
In the pediatric trial, 18 subjects (male and female ages 12 - 17) with interdigital tinea pedis and positive fungal cultures were treated with Dermazole topical foam, 1% once daily for 4 weeks. Subjects applied a mean daily amount of 3.2 g of Dermazole topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 28 at pre-dose and 7 h and 11 h post-dose. The mean ± SD econazole plasma concentration was 397 ± 289, 534 ± 745 and 575 ± 638 pg/mL at pre-dose and 7 h and 11 h post-dose, respectively.
12.4 Microbiology
Mechanism of Action
Dermazole, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the fungistatic activity of econazole. Mammalian cell demethylation is less sensitive to econazole inhibition.
Activity in vitro and in clinical infections
Dermazole has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage (1) ].
Trichophyton rubrum
Epidermophyton floccosum
Trichophyton mentagrophytes
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term animal studies to determine the carcinogenic potential of Dermazole topical foam have not been performed.
Oral administration of Dermazole in rats has been reported to produce prolonged gestation.
14 CLINICAL STUDIES
In two multi-center, randomized, double-blind, vehicle-controlled clinical trials a total of 505 subjects with interdigital tinea pedis were randomized 1:1 to Dermazole topical foam or vehicle; subjects applied the assigned medication once daily for 4 weeks. The severity of erythema, scaling, fissuring, maceration, vesiculation, and pruritus were graded using a 4-point scale (none, mild, moderate, severe). Subjects had KOH examination and fungal cultures taken to confirm eligibility. A total of 339 subjects with positive fungal cultures were evaluated for efficacy. Efficacy was evaluated on Day 43, 2 weeks post-treatment with treatment success being defined as complete cure (negative KOH and fungal culture and no evidence of clinical disease). The study population ranged in age from 12 to 71 years with 3 subjects less than 18 years of age at baseline. The subjects were 71% male and 52% Caucasian. Table 1 presents the efficacy results for each trial.
| Study 1 | Study 2 | |||
|---|---|---|---|---|
| Dermazole topical foam, 1% N = 82 n(%) | Foam Vehicle N = 83 n(%) | Dermazole topical foam, 1% N = 91 n(%) | Foam Vehicle N = 83 n(%) | |
| Complete cure | 19 (23.2%) | 2 (2.4%) | 23 (25.3%) | 4 (4.8%) |
| Effective treatment | 40 (48.8%) | 9 (10.8%) | 44 (48.4%) | 9 (10.8%) |
| Mycological cure | 56 (68.3%) | 13 (15.7%) | 61 (67.0%) | 15 (18.1%) |
16 HOW SUPPLIED/ STORAGE AND HANDLING
Dermazole topical foam, 1% is white to off-white foam supplied in 70 g (NDC 23710-100-70) aluminum pressurized canister.
Store at controlled room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). Do not refrigerate or freeze.
Dermazole topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application.
Contents under pressure. Do not puncture and/or incinerate the containers.
Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty.
Do not store in direct sunlight.
17 PATIENT COUNSELING INFORMATION
See FDA-approved patient labeling (Patient Information)
The patient should be instructed as follows:
- Inform patients that Dermazole (econazole nitrate) topical foam, 1% is for topical use only. Dermazole (econazole nitrate) topical foam, 1% is not intended for oral, intravaginal, or ophthalmic use.
- Dermazole topical foam, 1% is flammable; avoid heat, flame, and smoking during and immediately following application.
- If a reaction suggesting sensitivity or chemical irritation develops with the use of Dermazole topical foam, 1%, use of the medication should be discontinued.
Manufactured in the USA for
Exeltis USA Dermatology, LLC
Florham Park, NJ 07932
U.S, Patent 5,993,830
Issued: 07/2016
1007001-01
| Patient Information ECOZA® (ee-ko-zah) (econazole nitrate) topical foam, 1% |
|---|
| Important information: Dermazole topical foam is for use on skin only. Do not use Dermazole topical foam in your eyes or vagina. |
| What is Dermazole topical foam? Dermazole topical foam is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older. |
| What should I tell my doctor before using Dermazole topical foam? Before using Dermazole topical foam, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. |
| How should I use Dermazole topical foam? See the detailed Instructions for Use for information about how to use Dermazole topical foam.
|
What should I avoid while using Dermazole topical foam?
|
| What are the possible side effects of Dermazole topical foam? Dermazole topical foam may cause skin reactions at the treatment site. Tell your doctor if you have any skin reactions on the areas of your skin treated with Dermazole topical foam. These are not all the possible side effects of Dermazole topical foam. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How should I store Dermazole topical foam?
Keep Dermazole topical foam and all medicines out of the reach of children. |
| General information about the safe and effective use of Dermazole topical foam Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your doctor or pharmacist for information about Dermazole topical foam that is written for health professionals. Do not use Dermazole topical foam for a condition for which it was not prescribed. Do not give Dermazole topical foam to other people, even if they have the same symptoms that you have. It may harm them. |
| What are the ingredients in Dermazole topical foam? Active ingredient: Dermazole, USP Inactive Ingredients: dimethicone, glycerin, polysorbate 20, povidone, propylene glycol, stearic acid, trolamine, purified water and butane as a propellant. Manufactured in the USA for Exeltis USA Dermatology, LLC, Florham Park, NJ 07932 For more information call Exeltis USA Dermatology, LLC. at 1-877- 324-9349. This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 07/2016 |
Instructions for Use
ECOZA® (ee-ko-zah)
(econazole nitrate) topical foam, 1%
| Important information: Ecoza® topical foam is for use on skin only. Do not use Dermazole topical foam in your eyes or vagina. |
Parts of Dermazole topical foam Canister.
Figure A
How to apply Dermazole topical foam:
| Step 1: | Before you apply Dermazole topical foam, shake the Dermazole topical foam canister for about 5 seconds. |
| Step 2: | Remove the cap and turn the Dermazole topical foam canister upside down over the palm of your hand. |
| Step 3: | Press down firmly on the actuator until there is a small amount of foam about the size of a golf ball in the palm of your hand. |
| Figure B | Figure C |
| Step 4: | Use your finger-tips to scoop up small amounts of Dermazole topical foam and apply to the affected skin areas on your feet. Gently rub the foam into the skin. |
| Figure D | |
| Step 5: | You should apply Dermazole topical foam to your toes, to the spaces between your toes, and to the surrounding areas 1 time a day for 4 weeks or as prescribed by your doctor. |
| Step 6: | Replace the cap. Wash your hands after applying Dermazole topical foam. |
How should I store Dermazole topical foam?
- Store Dermazole topical foam at room temperature, between 68°F to 77°F (20°C to 25°C).
- Do not refrigerate or freeze Dermazole topical foam.
- Do not store Dermazole topical foam in direct sunlight.
- Dermazole topical foam is flammable. Keep the Dermazole topical foam canister away from heat and temperatures above 120°F (49°C), even if the canister is empty.
- Do not puncture or burn the Dermazole topical foam canister.
Keep Dermazole topical foam and all medicines out of the reach of children.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Manufactured in the USA for Exeltis USA Dermatology, LLC, Florham Park, NJ 07932
Issued: 07/2016
figure A figure b figure c Figure d
NDC 23710-100-70
Dermazole
(econazole nitrate)
topical foam, 1%
For Topical Use Only
Not for ophthalmic, oral or intravaginal use.
Keep Out of Reach of Children
Rx Only
Net Wt 70g
Exeltis
Rethinking healthcare
Dermazole pharmaceutical active ingredients containing related brand and generic drugs:
Dermazole available forms, composition, doses:
Dermazole destination | category:
Dermazole Anatomical Therapeutic Chemical codes:
Dermazole pharmaceutical companies:
References
- Dailymed."ECOZA (ECONAZOLE NITRATE) AEROSOL, FOAM [EXELTIS USA DERMATOLOGY, LLC]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
- "econazole". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
- "econazole". http://www.drugbank.ca/drugs/DB0112... (accessed August 28, 2018).
Frequently asked Questions
Can i drive or operate heavy machine after consuming Dermazole?Depending on the reaction of the Dermazole after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Dermazole not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Dermazole addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
Review
sdrugs.com conducted a study on Dermazole, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Dermazole consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.Visitor reports
Visitor reported useful
No survey data has been collected yetVisitor reported side effects
No survey data has been collected yetVisitor reported price estimates
No survey data has been collected yetOne visitor reported frequency of use
How often in a day do you take the medicine?Are you taking the Dermazole drug as prescribed by the doctor?
Few medications can be taken Once in a day more than prescribed when the doctor's advice mentions the medicine can be taken according to frequency or severity of symptoms. Most times, be very careful and clear about the number of times you are taking the medication. The report of sdrugs.com website users about the frequency of taking the drug Dermazole is mentioned below.
| Visitors | % | ||
|---|---|---|---|
| Once in a day | 1 | 100.0% | |
Visitor reported doses
No survey data has been collected yetVisitor reported time for results
No survey data has been collected yetVisitor reported administration
No survey data has been collected yetVisitor reported age
No survey data has been collected yetVisitor reviews
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology